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Abstract
Introduction: Triple negative breast cancer (TNBC) is very aggressive and currently has no specific therapeutic
targets, such as hormone receptors or human epidermal growth factor receptor type 2 (HER2); therefore, prognosis
is poor. Bortezomib, a proteasome inhibitor, may exert efficacy in TNBC through its multiple cellular effects. Here,
we tested the efficacy of bortezomib and examined the drug mechanism in breast cancer cells.
Methods: Five breast cancer cell lines: TNBC HCC-1937, MDA-MB-231, and MDA-MB-468; HER2-overexpressing
MDA-MB-453; and estrogen receptor positive MCF-7 were used for in vitro studies. Apoptosis was examined by
both flow cytometry and Western Blot. Signal transduction pathways in cells were assessed by Western Blot. Gene
silencing was done by small interfering RNA (siRNA). In vivo efficacy of bortezomib was tested in nude mice with
breast cancer xenografts. Immunohistochemical study was performed on tumor tissues from patients with TNBC.
Results: Bortezomib induced significant apoptosis, which was independent of its proteasome inhibition, in the
three TNBC cell lines, but not in MDA-MB-453 or MCF-7 cells. Furthermore, cancerous inhibitor of protein
phosphatase 2A (CIP2A), a cellular inhibitor of protein phosphatase 2A (PP2A), mediated the apoptotic effect of
bortezomib. We showed that bortezomib inhibited CIP2A in association with p-Akt downregulation in a dose- and
time-dependent manner in all sensitive TNBC cells, whereas no alterations in CIP2A expression and p-Akt were
noted in bortezomib-resistant cells. Overexpression of CIP2A upregulated p-Akt and protected MDA-MB-231 and
MDA-MB-468 cells from bortezomib-induced apoptosis, whereas silencing CIP2A by siRNA overcame the resistance
to bortezomib-induced apoptosis in MCF-7 cells. In addition, bortezomib downregulated CIP2A mRNA but did not
affect the degradation of CIP2A protein. Furthermore, bortezomib exerted in vivo antitumor activity in HCC-1937
xenografted tumors, but not in MCF-7 tumors. Bortezomib downregulated CIP2A expression in the HCC-1937
tumors but not in the MCF-7 tumors. Importantly, CIP2A expression is readily detectable in tumor samples from
TNBC patients.
Conclusions: CIP2A is a major determinant mediating bortezomib-induced apoptosis in TNBC cells. CIP2A may
thus be a potential therapeutic target in TNBC.
Introduction
Triple negative breast cancer (TNBC), which comprises
approximately 15% of all breast carcinomas [1], is
defined as breast carcinoma that does not express estro-
gen receptor (ER), progesterone receptor (PgR) or
human epidermal growth factor receptor type 2 (HER2).
These tumors are characterized by occurrence in
younger women, aggressive behaviors with a high recur-
rence rate, metastasis potential and poor prognosis
[1-3]. Because of a lack of targeted therapies (such as
hormone therapy or anti-HER2 therapy) for TNBC, che-
motherapy is currently the main treatment. There is,
therefore, an urgent and unmet need to develop targeted
therapy for TNBC. Discovering the critical molecular
mechanisms of TNBC and developing new compounds
targeting these mechanisms may advance the develop-
ment of TNBC treatments.
Bortezomib is the first proteasome inhibitor to be
approved for treatment for multiple myeloma and man-
tle cell lymphoma [4,5]. Bortezomib has been shown to
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block proteasome degradation of IB, an inhibitor of
nuclear factor-B (NF-B), and demonstrated remark-
able anti-tumor activity against these hematological
malignancies. The transcription factor NF-B is believed
to play a vital role in the action of bortezomib as it is
involved in cancer cell proliferation, apoptosis, invasion,
metastasis, tumorigenesis and angiogenesis [4-6]. In
addition, bortezomib affects several other cellular path-
ways, such as tumor suppressor protein p53, cell cycle
regulators p21, p27, proapoptotic (Noxa, bax, and so on)
and antiapoptotic (mcl-1, bcl-2, and so on) bcl-2 family
proteins that lead to apoptosis [7]. Preclinical studies
have demonstrated an in vitro antitumor effect of borte-
zomib in breast cancer models [8-10]. In the clinical
arena bortezomib as a single agent showed limited clini-
cal efficacy (objective response) in two single institu-
tional phase II clinical trials for patients with previously
treated metastatic breast cancers (MBC) [11,12]. In con-
trast, combinational trials of bortezomib with other
therapeutics for MBC seem promising: a phase II study
combining bortezomib with pegylated liposomal doxoru-
bicin demonstrated a response rate of 8% in patients
with MBC [13]; another phase I/II study showed that a
combination of bortezomib and capecitabine is well tol-
erated and has moderate antitumor activity (15% overall
response rate) in heavily pretreated MBC patients [14];
and another phase I/II study combining bortezomib
with docetaxel showed a more promising response rate
of 38% at the maximum tolerated dose for anthracy-
cline-pretreated advanced/metastatic breast cancer [15].
Bortezomib is currently being tested in combination
with fulvestrant, a novel estrogen antagonist, in a rando-
mized phase II study for patients with ER positive MBC
(NCT01142401). Although the reason why the single
bortezomib regimen is not significantly active in clinical
trials might be explained by the possibility of the activa-
tion of multiple drug resistance pathways in heavily pre-
treated populations, particularly those previously
exposed to anthracycline [16], alternative mechanisms
might also confer sensitivity to bortezomib in patients
with breast cancers. Interestingly, in the phase II study
by Yang et al. [12], the inhibition of proteasome activity
was measured in bortezomib-treated patients and did
not translate into a meaningful therapeutic benefit in
these patients, implying that bortezomib’s mechanism of
action may not necessarily depend on its proteasome
inhibitory effect [12]. Therefore, the exact anti-tumor
mechanisms of bortezomib in breast cancers, and to our
interest TNBC, warrant further elucidation.
In this regard, our previous study showed that down-
regulation of phospho-Akt (p-Akt) plays a key role in
determining the sensitivity of hepatocellular carcinoma
(HCC) cells to bortezomib-induced apoptosis [17].
Importantly, we found that the differential cytotoxic
effects of bortezomib on HCC are independent of its
proteasome inhibition [17]. Akt is a well-known key
player in cancer cell survival and apoptosis regulation.
It is noteworthy that activated p-Akt signaling has
been shown to be higher in TNBC tumor samples than
in other breast tumor types [18]. Negative regulation of
Akt signaling can be achieved by phosphatases, such as
phosphatase and tensin homologue deleted on chro-
mosome ten (PTEN), and protein phosphatase 2A
(PP2A). PTEN dephosphorylates phosphatidylinositol
3, 4, 5-triphosphate (PIP3) at the 3-position to coun-
teract phosphatidylinositol-3-kinase (PI3K), thereby
inhibiting Akt signaling. In contrast, PP2A is a com-
plex serine/threonine protein phosphatase that can
directly dephosphorylate oncogenic kinases such as p-
Akt and p-ERK [19], by which PP2A can function as a
tumor suppressor through regulating apoptosis, cell
cycle, cell survival and proliferation [20]. Our recent
data indicated that the bortezomib enhances PP2A
activity thereby downregulating p-Akt and inducing
apoptosis in HCC cells [21]. We also found that borte-
zomib can act synergistically with sorafenib to induce
apoptosis in HCC cells through this PP2A-dependent
p-Akt inactivation [22]]. In addition, several cellular
upstream inhibitors of PP2A such as SET [23], and
cancerous inhibitor of protein phosphatase 2A (CIP2A)
[24] have been identified. SET is a nucleus/cytoplasm-
localized phosphoprotein that has been shown to be
predominantly a myeloid leukemia-associated protein
[25]. In contrast, CIP2A has emerged as a novel onco-
protein and a growing number of reports have shown
its overexpression in many human malignancies,
including breast cancers [21,24,26-31]. CIP2A has been
shown to promote anchorage-independent cell growth
and in vivo tumor formation by inhibiting PP2A activ-
ity toward c-Myc [32]. Importantly, Come et al. [33]
found that CIP2A is associated with clinical aggressive-
ness in human breast cancer and promotes the malig-
nant growth of breast cancer cells, suggesting CIP2A
as a new target for breast cancer therapy.
In this study, we revealed that CIP2A, a cellular inhi-
bitor of protein phosphatase 2A (PP2A), mediated the
apoptotic effect of bortezomib. Bortezomib induced sig-
nificant apoptosis in TNBC cell lines but not in hor-
mone receptor positive or HER2-overexpressing cells.
Our data indicate that bortezomib’s downregulation of
CIP2A and p-Akt correlated with its drug sensitivity.
Through ectopic overexpression and silencing CIP2A,
we confirmed that CIP2A is the predominant mediator
of bortezomib-induced apoptosis in TNBC cells. This
CIP2A-dependent p-Akt inhibitory mechanism that
mediates the efficacy of bortezomib was confirmed in
vivo in a nude mouse model. Furthermore, CIP2A
expression can be demonstrated in tumor samples from
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TNBC patients. Our results suggest that CIP2A may be
a novel therapeutic target for treatment of TNBC.
Materials and methods
Reagents and antibodies
Bortezomib (Velcade®) was kindly provided by Millen-
nium Pharmaceuticals (Cambridge, MA, USA)For in
vitro studies, bortezomib at various concentrations was
dissolved in dimethyl sulfoxide (DMSO) and then added
to cells in (D)MEM medium (Invitrogen, Carlsbad, CA,
USA). The final DMSO concentration was 0.1% after
addition to the medium. Antibodies for immunoblotting
such as anti-I-B and CIP2A were purchased from
Santa Cruz Biotechnology (San Diego, CA, USA). Other
antibodies such as anti-caspase-3, Akt, and P-Akt
(Ser473) were from Cell Signaling (Danvers, MA, USA).
Cell culture and western blot analysis
The HCC-1937, MDA-MB-231, MDA-MB-468, MDA-
MB-453 and MCF-7 cell lines were obtained from
American Type Culture Collection (Manassas, VA,
USA). All breast cancer cells were maintained in (D)
MEM medium supplemented with 10% FBS, 0.1 mM
nonessential amino acids (NEAA), 2 mM L-glutamine,
100 units/mL penicillin G, 100 μg/mL streptomycin sul-
fate, and 25 μg/mL amphotericin B in a 37°C humidified
incubator and an atmosphere of 5% CO2 in air. Lysates
of breast cancer cells treated with drugs at the indicated
concentrations for various periods of time were pre-
pared for immunoblotting of caspase-3, P-Akt, Akt,
CIP2A, and so on. Western blot analysis was performed
as previously reported [17].
Apoptosis analysis
Drug-induced apoptotic cell death was assessed using
the following methods: (a) Western blot analysis of cas-
pase activation or poly ADP-ribose polymerase (PARP)
cleavage (in caspase deficient MCF-7 cells), and (b) mea-
surement of apoptotic cells by flow cytometry (sub-G1
analysis).
Proteasome inhibitory activity
A 20S Proteasome Activity Assay kit (Chemicon Inter-
national, Temecula, CA, USA) was used to determine
the proteasome inhibition in drug-treated cells. All pro-
cedures were conducted according to the manufacturer’s
instructions [17]. In brief, cells were treated with or
without bortezomib for the indicated length of time.
Then, cells were lysed and total protein was quantified.
Equal amounts of total protein of each sample were
used for incubation with the proteasome substrate
(fluorophore-labeled substrate). Proteasome activity
measurement was based on detection of the fluorophore
after cleavage from the labeled substrate by a fluorom-
eter with a 380/460 nm filter set.
Gene knockdown using siRNA
Smartpool siRNA reagents, including control (D-
001810-01), and CIP2A were all purchased from Dhar-
macon (Chicago, IL, USA). The procedure has been
described previously [17]. Briefly, cells were transfected
with siRNA (final concentration, 100 nM) in six-well
plates using the Dharma-FECT1 transfection reagent
(Dharmacon) according to the manufacturer’s instruc-
tions. After 72 hours, the medium was replaced and the
breast cancer cells were incubated with bortezomib, har-
vested, and separated for western blot analysis and for
apoptosis analysis by flow cytometry.
Generation of MDA-MB-231 and MDA-MB-468 cells with
constitutive active CIP2A
Cells were transfected with active CIP2A construct by
procedures as previously described [26]. Briefly, follow-
ing transfection, cells were incubated in the presence of
G418 (1.40 mg/mL). After eight weeks of selection, sur-
viving colonies, that is, those arising from stably trans-
fected cells, were selected and individually amplified.
CIP2A cDNA (KIAA1524) was purchased from Origene
(RC219918; Rockville, MD, USA) and constructed into
pCMV6 vector.
Xenograft tumor growth
NCr athymic nude mice (five to seven weeks of age)
were obtained from the National Laboratory Animal
Center (Taipei, Taiwan). The mice were housed in
groups and maintained in a specific pathogen free
(SPF)-environment. All experimental procedures using
these mice were performed in accordance with protocols
approved by the Institutional Animal Care and Use
Committee of Taipei Veterans General Hospital. Each
mouse was inoculated s.c. in the dorsal flank with 2 to 4
× 106 breast cancer cells suspended in 0.1 to 0.2 mL
serum-free medium containing 50% Matrigel (BD Bios-
ciences, Bedford, MA, USA) under isoflurane anesthesia.
Tumors were measured using calipers and their volumes
calculated using a standard formula: width2 × length ×
0.52. When tumors reached 100 mm3, mice were admi-
nistered an i.p. injection of bortezomib (0.5 mg/kg body
weight) twice weekly for three to four weeks. Controls
received vehicle.
Reverse transcription-PCR
Total RNA was extracted from cultured cells using TRI-
zol® Reagent (Invitrogen, San Diego, CA, USA) and RT-
PCR was performed according to the manufacturer’s
instructions (MBI Fermentas, Vilnius, Lithuania). RT-
Tseng et al. Breast Cancer Research 2012, 14:R68
http://breast-cancer-research.com/content/14/2/R68
Page 3 of 14
PCR analyses were performed as previously described,
using specific primers for human CIP2A (forward, 5’-
TGGCAAGATTGACCTGGGATTTGGA-3’; reverse, 5’-
AGGAGTAATCAAACGTGGGTCCTGA-3’; 172 bps);
the GAPDH (glyceraldehyde-3-phosphate dehydrogen-
ase) gene (forward, 5’-CGACCACTTTGTCAAGCTCA-
3’; reverse, 5’-AGGGGTCTACAT GGCAACTG-3’; 228
bps) was chosen as an internal control.
Real-time quantitative PCR was performed in a Light-
Cycler 480II instrument (Roche Diagnostics, Indianapo-
lis, IN, USA) using a LightCycler 480 SYBR Green I
Master kit (Roche). Primers are the same as above
described.
Immunohistochemical staining
Paraffin-embedded tissue microarray of tumor samples
from TNBC patients’ sections (4-μm) on poly-1-lysine-
coated slides were first de-waxed in xylene and re-
hydrated through graded alcohols, followed by a rinse
using 10 mM Tris-HCl (pH 7.4) and 150 mM sodium
chloride, then treated with 3% hydrogen peroxide for
five minutes. Slides were incubated with a 1:100 dilution
of rabbit polyclonal anti-p90 autoantigen (CIP2A) anti-
body (ab84547) (Abcam, Cambridge, UK) for one hour
at room temperature, then thoroughly washed three
times with PBS. Bound antibodies were detected using
the LSAB+ kit (Dako, Glostrup, Denmark). The slides
were then counterstained with hematoxylin stain solu-
tion. Paraffin-embedded sections of human colon carci-
noma and ovarian carcinoma of cytoplasmic
immunoreactivity were used as positive controls. Nega-
tive controls had the primary antibody omitted and
replaced by PBS. CIP2A immunoreactivity was scored as
negative, weak, moderate, and strong expression,
respectively.
This study was approved by the ethics committee of
the Institutional Review Board of Taipei Veterans Gen-
eral Hospital. All informed consents from sample
donors were in accordance with the Declaration of Hel-
sinki and were obtained at time of their donation.
Statistical analysis
Data are expressed as mean ± standard deviation (SD)
or standard error (SE). Statistical comparisons were
based on nonparametric tests and statistical significance
was defined at P < 0.05. All statistical analyses were per-
formed using SPSS for Windows software, version 12.0
(SPSS, Inc., Chicago, IL, USA).
Results
Differential apoptotic effects of bortezomib on breast
cancer cells
To investigate the antitumor effect of bortezomib on
breast cancer cells, we first assessed the apoptotic effect
of bortezomib in a panel of five human breast cancer
cell lines: TNBC cells HCC-1937, MDA-MB-231, and
MDA-MB-468; HER2-overexpressing cells MDA-MB-
453; and estrogen receptor positive cells MCF-7. Flow
cytometry analysis of sub-G1 cells showed that bortezo-
mib induced differential apoptotic effects at the indi-
cated doses (50, 100 and 500 nM) on the five breast
cancer cell lines (Figure 1A). Bortezomib induced apop-
tosis in a dose- and time-dependent manner in HCC-
1937, MDA-MB-231, and MDA-MB-468 cells, whereas
no apparent apoptotic effects were elicited by bortezo-
mib in MCF-7 and MDA-MB-453 cells at doses up to
500 nM at 12, 24, and 36 hours of treatment (Figure
1A). These data indicate that triple negative breast can-
cer cell lines HCC-1937, MDA-MB-231, and MDA-MB-
468 cells were sensitive to the cytotoxic activity of bor-
tezomib, whereas MCF-7 and MDA-MB 453 cells were
resistant.
Bortezomib exerts similar, efficient proteasome inhibition
in both sensitive and resistant breast cancer cells
To explore the mechanism by which bortezomib
induces apoptosis in these breast cancer cell lines, we
first examined the proteasome inhibitory effects of bor-
tezomib in the cell lines. Proteasome activity was mea-
sured in the five cell lines after treatment for 24 hours
with bortezomib. As shown in Figure 1B, bortezomib
treatment resulted in similar dose-dependent effects on
proteasome inhibition in all five breast cancer cell lines.
Previous studies have shown that bortezomib inhibited
NF-kB signaling through inhibiting the proteasome
degradation of IkB (inhibitor of NF-kB) [4-6]. Therefore,
we next examined the cytoplasmic protein levels of IkB
in sensitive HCC-1937, MDA-MB-231, and MDA-MB-
468 cells and resistant MCF-7 and MDA-MB-453 cells
treated with bortezomib (Figure 1C). Notably, bortezo-
mib increased the cytoplasmic protein levels of IB-a
both in sensitive and resistant cells, suggesting similar
proteasome inhibition in all these cells. These results
suggest that the differential induction of apoptosis by
bortezomib in breast cancer cells may not necessarily be
dependent on proteasome inhibition, which is consistent
with our previous findings in HCC cells [17].
Bortezomib induces apoptosis by downregulating CIP2A
and p-Akt in sensitive TNBC cells
Our previous study demonstrated that the CIP2A-PP2A-
AKT pathway mediated the sensitizing effect of bortezo-
mib on tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL)-induced cell apoptosis in HCC [21].
Here we examined the molecular events associated with
apoptosis and investigated the effects of bortezomib on
p-Akt and CIP2A in bortezomib-treated breast cancer
cells. As shown in Figure 2, bortezomib downregulated
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protein levels of CIP2A and induced apoptosis in sensi-
tive HCC-1937, MDA-MB-231 and MDA-MB 468 cells
in a dose-dependent manner (Figure 2A). Furthermore,
inhibition of CIP2A was associated with downregulation
of p-Akt and induction of apoptosis which was evi-
denced by the activation (cleavage) of caspase-3 in sensi-
tive cells (Figure 2A). In contrast, bortezomib did not
affect protein levels of CIP2A or P-Akt or induction of
apoptosis in resistant MCF-7 and MDA-MB-453 cells
(Figure 2A). It should be noted that we used PARP clea-
vage instead of caspase-3 for assessment of apoptotic
events in the MCF-7 cell line because previous studies
have shown that MCF-7 cells do not express caspase-3
due to the functional deletion of the CASP-3 gene
Figure 1 Differential apoptotic effects and similar proteasome inhibition induced by bortezomib in breast cancer cells. A, Dose- and
time-escalation effects of bortezomib (50 nM, 100 nM and 500 nM) on apoptosis in five breast cancer cell lines (HCC-1937, MDA-MB-231, MDA-
MB-468, MCF-7 and MDA-MD-453). Cells were exposed to bortezomib at the indicated doses for 12, 24 and 36 hours. Apoptotic cells were
determined by flow cytometry. Columns, mean (n = 3); bars, SD; *P < 0.05. B, Bortezomib exerted an efficient and similar dose-dependent effect
on proteasome inhibition as measured by proteasome activity assays in the five breast cancer cell lines. Cells were exposed to bortezomib at the
indicated doses for 24 hours before measurement of proteasome activity. Columns, mean (n = 3); bars, SD; *P < 0.05. C, Bortezomib increased
cytoplasmic protein levels of IB-a, a cellular inhibitor of NF-B and a known proteasome substrate, both in sensitive (HCC-1937, MDA-MB-231
and MDA-MB-468) and resistant (MCF-7 and MDA-MB-453) cells, suggesting similar proteasome inhibition in all these cells. Cells were treated
with DMSO or 500 nM bortezomib at the indicated time point. Cytoplasmic extracts were prepared and assayed for IB-a by western blot. Data
are representative of three independent experiments. DMSO, dimethyl sulfoxide; SD, standard deviation.
Tseng et al. Breast Cancer Research 2012, 14:R68
http://breast-cancer-research.com/content/14/2/R68
Page 5 of 14
[34-36]. In addition, relative expression levels of CIP2A,
p-Akt and Akt among all the cell lines tested were also
shown, and the intrinsic expression levels of these mole-
cules seemed not to be correlated with bortezomib drug
sensitivity (Figure 2A). Figure 2B shows the quantified
ratio of CIP2A to actin levels as scanned from the cell
lysates in Figure 2A and demonstrates the significant
downregulation of CIP2A by bortezomib in sensitive
Figure 2 Bortezomib downregulated CIP2A, p-Akt and induced cleavage of caspase 3 in a dose- and time-dependent manner. A, Dose-
dependent analysis of CIP2A, p-Akt and caspase-3. Cells were exposed to bortezomib at the indicated doses for 36 hours. Cell lysates were prepared
and assayed for these molecules by western blotting. Data are representative of three independent experiments. CF, cleaved form (activated form).
Note that PARP cleavage, instead of caspase-3, was used for assessment of apoptosis in MCF-7 cells since previous studies have shown that MCF-7
cells do not express caspase-3 due to the functional deletion of the CASP-3 gene [34-36]. Lower right, relative expression levels of CIP2A, p-Akt and Akt
among all the cell lines tested are also shown. B, Ratio of CIP2A to actin levels from the cell lysates in (A). Immunoblots were scanned by a UVP
BioSpectrum AC image system and quantitated using VisionWork LS software. Columns, mean (n = 3); bars, SD. C, Time-dependent analysis of CIP2A,
p-Akt and caspase-3. Cells were exposed to bortezomib at 500 nM for the indicated time points. Data are representative of three independent
experiments. CIP2A, cancerous inhibitor of PP2A; PARP, poly ADP-ribose polymerase; SD, standard deviation.
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cells in contrast with no significant alteration in CIP2A
level in resistant cells. Similar effects of bortezomib on
p-Akt and CIP2A can be seen in a time-dependent man-
ner in bortezomib-treated breast cancer cells (Figure
2C). These results suggest that inhibition of CIP2A may
be the major determinant of bortezomib-induced apop-
tosis in breast cancer cells.
Target validation of CIP2A as a molecular determinant for
bortezomib-induced apoptosis
To validate the role of CIP2A signaling in mediating the
apoptotic effect of bortezomib in breast cancer cells, we
first generated MDA-MB- 231-CIP2A and MDA-MB-
468-CIP2A cells which constitutively express ectopic
CIP2A (Figure 3A). Notably, MDA-MB-231-CIP2A and
MDA-MB-468-CIP2A cells also expressed constitutively
activated p-Akt, and constitutive ectopic expression of
CIP2A protected sensitive MDA-MB 231 and MDA-MB
468 cells from apoptotic death induced by bortezomib
(Figure 3A). Next, we knocked down protein expression
of CIP2A in resistant MCF-7 cells by using siRNA. As
shown in Figure 3B, downregulation of CIP2A sensitized
resistant MCF-7 cells to bortezomib-induced apoptosis
(Figure 3A). These results indicate that CIP2A plays a
key role in mediating the apoptotic effect of bortezomib
in breast cancer cells.
Bortezomib downregulates transcription of CIP2A in
breast cancer cells
To examine the effects of bortezomib on CIP2A expres-
sion, we first examined whether bortezomib could affect
CIP2A elimination (degradation) when translation was
blocked by the protein synthesis inhibitor cyclohexi-
mide. Our data showed that after protein translation
was blocked by cycloheximide, the rate of CIP2A degra-
dation did not change significantly with or without bor-
tezomib treatment in any of the three sensitive TNBC
lines (HCC-1937, MDA-MB-231, and MDA-MB-468)
(Figure 4A), suggesting that the effect of bortezomib on
CIP2A may occur at the pre-translation level and that
CIP2A might not be the proteasome degradation sub-
strate. We next investigated whether bortezomib
affected CIP2A transcription. As shown in Figure 4B,
mRNA levels of CIP2A (as measured by a semi-quanti-
tative nested PCR), decreased in a time-dependent man-
ner upon treatment with bortezomib in the three
sensitive breast cancer cell lines. Similarly, we performed
real-time quantitative PCR analysis and showed that
bortezomib inhibited mRNA levels of CIP2A in a dose-
dependent manner in sensitive cell lines (Figure 4C, left)
but not in resistant cell lines (Figure 4C, right). Failure
of inhibiting CIP2A transcription by bortezomib sug-
gests drug-resistance. Further studies are indicated to
unravel the mechanisms underlying resistance to
bortezomib-induced down regulation of CIP2A in MCF-
7 and MDA-MB-453 cells.
Effect of bortezomib on breast cancer xenograft tumor
growth in vivo
To confirm that the effect of bortezomib on CIP2A has
potentially relevant clinical implications in breast cancer,
we assessed the in vivo effect of bortezomib on breast
cancer xenograft tumors. HCC-1937 xenografted and
MCF-7 xenografted tumor mice were generated to vali-
date the role of CIP2A in vivo. Tumor-bearing mice
were treated with vehicle or bortezomib i.p. at the clini-
cally relevant dose of 1 mg/kg twice a week for three to
four weeks. As shown in Figure 5, bortezomib signifi-
cantly inhibited HCC-1937 tumor growth (P < 0.05) and
the mean tumor size in the bortezomib treatment group
was about 40% that of control at the end of treatment
(Figure 5A, left). The mean tumor weight was also sig-
nificantly reduced in bortezomib-treated mice (Figure
5B, left). In contrast, bortezomib did not inhibit MCF-7
tumor growth, as measured by tumor size (Figure 5A,
right) and tumor weight (Figure 5B, right). To correlate
the biological response with the mechanism of action
identified in vitro, the effect of bortezomib on CIP2A in
these tumors was examined by western blot. Figure 5C
shows western blots of CIP2A, p-Akt, Akt, and PARP
cleavage in the homogenates of three representative
HCC-1937 and MCF-7 tumors. Overall, there was a sig-
nificant decrease in CIP2A as well as p-Akt and evident
apoptosis (as shown by PARP cleavage) in HCC-1937
tumors treated with bortezomib, whereas no significant
change was observed in control (vehicle) or MCF-7
tumors (Figure 5C). Importantly, all animals tolerated
the treatments well without observable signs of toxicity
and had stable body weights throughout the course of
the study (Figure 5D). No gross pathologic abnormalities
were noted at necropsy. Finally, we examined whether
bortezomib also inhibited other TNBC xenograft tumors
in vivo. As shown in Figure 5E, bortezomib significantly
inhibited MDA-MB-231 and MDA-MB-468 tumor
growth in vivo.
CIP2A expression in breast tumor tissue from patients
with TNBC
Previous study showing CIP2A expression in breast can-
cer has mainly been based on mRNA expression [33]. In
the current study, we performed immunohistochemical
(IHC) staining of CIP2A in a tissue array of 57 tumor
samples from TNBC patients. Results showed that 50/57
(87.7%) tumors demonstrated variable CIP2A expres-
sion, among which 18(36%), 12(24%), and 20(40%) cases
exhibited weak, moderate, and strong expression,
respectively. Figure 6 demonstrates representative results
of IHC staining for CIP2A, showing negative (A), weak
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expression (B), moderate expression (C), and strong
expression (D). In contrast to the variable expression in
cancer cells, normal stromal tissue in the adjacent areas
of cancer did not stain with CIP2A (Figure 6A to 6D).
Figure 6E shows a positive control from human colon
carcinoma and ovarian carcinoma with cytoplasmic
immunoreactivity (Figure 6E, left and middle) and a
negative control which had the primary CIP2A antibody
Figure 3 Target validation of CIP2A. A, Ectopic expression of CIP2A protected MDA-MB-231 (left) and MDA-MB-468 (right) cells from the
apoptotic effect of bortezomib. Note that MDA-MB-231 and MDA-MB-468 cells with ectopic expression of CIP2A also had constitutively higher
expression of p-Akt compared to wild-type cell clones. Columns, mean (n = 3); bars, SD; *P < 0.05. Cells were transfected with CIP2A and were
selected for eight weeks by G-418. Analysis of apoptotic cells was performed by flow cytometry after cells were sequentially exposed to DMSO
or bortezomib 500 nM for 36 hours. B, Downregulation of CIP2A by siRNA increased bortezomib-induced apoptosis in MCF-7 cells. Columns,
mean (n = 3); bars, SD; *P < 0.05. Cells were transfected with either control (scrambled siRNA) or CIP2A siRNA for 48 h oursand then exposed to
bortezomib at 1000 nM for 36 hours. CIP2A, cancerous inhibitor of PP2A; DMSO, dimethyl sulfoxide; SiRNA, small interfering RNA; SD, standard
deviation.
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replaced by PBS (Figure 6E, right). Further studies as
well as more samples are warranted to clarify the clini-
cal role of CIP2A among various subtypes of breast can-
cer, in addition to TNBC subtypes.
Discussion
This study reveals a novel mechanism by which bortezo-
mib induces apoptosis in triple negative breast cancer
cells (that is, CIP2A-dependent p-Akt downregulation).
Figure 4 Bortezomib downregulates transcription of CIP2A. A, After cells were treated with 100 μg/ml translation inhibitor cyclohexamide
(CHX) in the presence or absence of 500 nM bortezomib for the indicated length of time, the stability of CIP2A protein in whole-cell lysates
were assessed by western blot. In bortezomib-sensitive cells (HCC 1937, MDA-MB-231, and MDA-MB-468), the addition of bortezomib did not
affect CIP2A degradation. B, Bortezomib inhibits CIP2A mRNA in a time-dependent manner. Cells were treated with bortezomib at 500 nM for
the indicated length of time, after which total RNA was isolated and CIP2A mRNA were semi-quantified using PCR as described in Methods.
Columns, mean (n = 3); bars, SD. C, Bortezomib inhibits CIP2A mRNA in a dose-dependent manner in sensitive cells (left), but not in resistant
cells (right). Cells were treated with bortezomib at the indicated doses for 36 hour, after which total RNA was isolated and CIP2A mRNA was
analyzed by real-time quantitative PCR (qRT-PCR). Columns, mean (n = 3); bars, SD. CIP2A, cancerous inhibitor of PP2A; PCR, polymerase chain
reaction; SD, standard deviation.
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Figure 5 In vivo effect of bortezomib on human breast cancer cell lines xenograft nude mice. A, Bortezomib decreased the size of HCC
1937 tumors (left), but had no anti-tumor effects on MCF-7 tumors (right). Points, mean (n = 6); bars, SE; * P < 0.05. B, Bortezomib reduced the
weight of HCC 1937 tumors (left), but had no effect on that of MCF-7 tumors (right). Columns, mean (n = 6); bars, SD; * P < 0.05. C, Western
blot analysis of CIP2A, p-Akt, Akt, and PARP cleavage in HCC 1937 and MCF-7 tumors. In vivo evidence of apoptosis is shown by PARP cleavage
in HCC1937 tumors. D, Body weight of xenograft mice bearing HCC 1937 tumors (left) and MCF-7 tumors (right) during the in vivo experiment.
Points, mean (n = 6); bars, SE. E, Bortezomib inhibited tumor growth of another two triple negative breast tumor xenografts (MDA-MB-231 and
MDA-MB-468). Points, mean (n = 6); bars, SE; * P < 0.05. Male NCr athymic nude mice (five to seven weeks of age) were used for experiments (A)
to (D), and female athymic nude mice were used for experiment (E). Mice were treated with intra-peritoneal injections of bortezomib (1 mg/kg
body weight) twice weekly. Controls received vehicle. CIP2A, cancerous inhibitor of PP2A; HCC, hepatocellular carcinoma; PARP, poly ADP-ribose
polymerase; SD, standard deviation; SE, standard error.
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This finding has several potentially important implica-
tions: First, we identified CIP2A as a molecular determi-
nant of cell sensitivity to bortezomib-induced apoptosis
and demonstrated that bortezomib-induced apoptosis
does not necessarily depend on its proteasome inhibi-
tion. We showed that bortezomib exerts similar
proteasome inhibitory effects in sensitive and resistant
cells as demonstrated by proteasome activity analysis
and by efficient I-kB (a proteasome substrate) accumula-
tion (Figure 1B and 1C). In contrast, bortezomib
induced differential apoptotic effects in these breast can-
cer cells, which correlated with CIP2A downregulation
Figure 6 Variable CIP2A expression in breast tumor tissue from patients with triple negative breast cancers. Representative results of
immunohistochemical staining for CIP2A in breast tumor tissue from patients with triple negative breast cancers, showing variable degree of
CIP2A expression ranging from negative (A), weak (B), moderate (C), and strong (D) expression. E. Detection of human CIP2A cytoplasmic
expression in colon carcinoma (left) and ovarian carcinoma (middle) by immunohistochemistry was used as positive control. Primary CIP2A
antibody omitted and replaced by phosphate-buffered saline was performed as negative control in TNBC (right). (High power, 400X).
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(Figure 2 and 3). This in vitro finding was supported by
previous in vivo evidence showing that bortezomib-
induced proteasome inhibition did not correlate well
with clinical therapeutic benefit in patients with breast
cancers in a phase II study [12]. Indeed, despite the
excellent anti-cancer activity of bortezomib in multiple
myeloma and mantle cell lymphoma via its proteasome
inhibition, cumulative clinical data have shown that bor-
tezomib is less efficient or shows transient anti-cancer
activity in solid tumors and other hematological malig-
nancies [11,12,37-39]. Our data may, further, partly
explain why bortezomib showed limited anti-tumor
activity in breast cancer patients in the phase II trials
[11,12]. In addition to the several known mechanisms of
bortezomib resistance in cancers [4,40], the CIP2A-
PP2A-p-Akt pathway may contribute to bortezomib
resistance. Future studies correlating response to borte-
zomib with downregulation and/or pre-treatment
expression levels of CIP2A in breast cancer patients may
help to establish a clinical role for CIP2A as a predictive
factor in breast cancer.
Second, our data strengthen the case for the use of
CIP2A as an anti-cancer target. Accumulating evidence
from our studies and the studies of others suggests that
targeting CIP2A may be an ideal approach
[26,32,33,41-43]. CIP2A expression is very low in most
human tissues and, importantly, undetectable in normal
mammary glands [32,33], thereby creating a potential
therapeutic window for CIP2A targeting agents. Come
et al. [33] demonstrated that depletion of CIP2A by
siRNA inhibits tumor growth of MDA-MB-231 xeno-
graft tumors. Our in vivo data also showed bortezomib
downregulated CIP2A in HCC-1937 xenograft tumors
and inhibited their tumor growth (Figure 5A to 5C).
Moreover, it has been shown that the traditional che-
motherapeutic agent doxorubicin downregulates CIP2A
expression and that increased CIP2A expression confers
doxorubicin resistance in breast cancer cells [44]. More
recently, a natural Chinese medicinal herbal extract of
Rabdosia coetsa, rabdocoetsin B, was also shown to inhi-
bit proliferation and induce apoptosis in a variety of
lung cancer cells via CIP2A-dependent p-Akt downregu-
lation [43]. Taken together, these structurally unrelated
agents show a common target in various cancer cells
suggesting that CIP2A is a novel anti-cancer target.
Our data showed that 50/57 (87.7%) tumor samples
from TNBC patients demonstrated variable CIP2A
expressions. As stated earlier, CIP2A expression has
been shown to correlate with disease aggressiveness [33]
in breast cancer. Higher CIP2A expression has been
shown as a prognostic factor predicting survival in gas-
tric cancer [29], non-small cell lung cancer [27,45],
renal cell carcinoma [46], serous ovarian cancer [47]
and early stage tongue cancer [47]. Very recently, an
IHC-based study [48] demonstrated that the CIP2A sig-
nature clustered with basal-type and HER2-positive
breast cancer signatures and suggested that CIP2A is
linked to these two subtypes of breast cancer. It would
also be interesting to further investigate the prognostic
role of CIP2A among various subtypes of breast cancer,
in addition to TNBC subtypes, by large immunohisto-
chemistry-based studies.
Despite the current results, the detailed mechanism by
which bortezomib inhibits CIP2A remains unknown and
further mechanistic studies are needed. Our data
showed that bortezomib did not affect the half-life of
CIP2A protein degradation after translation was stopped
by cyclohexamide and that bortezomib suppressed
CIP2A transcription (Figure 5), suggesting that the effect
of bortezomib on CIP2A occurs pre-translation and is
possibly irrelevant to its proteasome inhibition. The pos-
sible mechanisms through which bortezomib may affect
the transcription of CIP2A include direct or indirect
promoter regulation of CIP2A mRNA, epigenetic regula-
tion of the CIP2A gene by DNA methylation or micro-
RNA machinery, or affecting other uncovered molecules
that regulate CIP2A expression.
Conclusions
Bortezomib shows a favorable apoptosis-inducing effect
in TNBC cells through a novel mechanism: CIP2A-
dependent p-Akt downregulation. This study identified
CIP2A as a major molecular determinant of the sensi-
tivity of TNBC cells to bortezomib-induced apoptosis.
This study also suggests that focusing on the interac-
tions of oncoproteins, phosphatases and kinases could
be a novel anti-cancer strategy. Future studies defining
CIP2A as a useful therapeutic biomarker for breast can-
cer patients, as well as the detailed mechanism by
which bortezomib inhibits CIP2A may lead to further
progress in the development of molecular-targeted ther-
apy for TNBC.
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